<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080767</url>
  </required_header>
  <id_info>
    <org_study_id>M-10331</org_study_id>
    <secondary_id>S-11-10</secondary_id>
    <nct_id>NCT02080767</nct_id>
  </id_info>
  <brief_title>Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure</brief_title>
  <official_title>Clinical Protocol to Treat Individuals With Tecovirimat (ST-246) After Exposure to Orthopox Viruses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure
      to orthopox viruses.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Smallpox</condition>
  <condition>Monkeypox</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tecovirimat</intervention_name>
    <description>Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)</description>
    <other_name>ST 246</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DoD-affiliated personnel (including US civilian employees, contractors and other US
             personnel and dependents, as well as allied military forces and local nationals) of
             any age, not breastfeeding

          -  Has been exposed to or infected with orthopox viruses (ie, variola (smallpox),
             vaccinia, monkeypox, or cowpox) OR Has developed serious complications from vaccinia
             vaccination (eg, eczema vaccinatum, progressive vaccinia, generalized vaccinia that is
             severe or persistent, and select cases of inadvertent inoculation due to severe pain
             related to mucosal involvement, ocular involvement) resulting from vaccination,
             secondary transmission, or other exposure

          -  Is available for clinical follow-up for duration of the treatment and follow-up period

          -  Must be able to swallow capsules

        Exclusion Criteria:

          -  Has hypersensitivity to tecovirimat

          -  Unable or unwilling to cooperate with the requirements of the treatment protocol

          -  Breast-feeding patients. Note that breast-feeding females will be counseled that
             tecovirimat has not been studied in breast-feeding women and may opt to cease
             breast-feeding for the duration of the treatment and at least 30 days after the last
             dose of drug and thus be eligible for enrollment. Women who choose to continue
             breast-feeding will not be enrolled in this treatment protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Frances K Devlin</last_name>
    <phone>301-619-9904</phone>
    <email>frances.k.devlin.ctr@mail.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James W Karaszkiewicz, PhD</last_name>
    <phone>301-619-6809</phone>
    <email>James.W.Karaszkiewicz.ctr@mail.mil</email>
  </overall_contact_backup>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
    <mesh_term>Monkeypox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

